PROK
Prokidney Corp
NASDAQ · Biotechnology
$1.87
+0.14 (+8.09%)
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 240.7K | 45.98M | 42.93M | 40.88M |
| Net Income | -187,991,407 | 9.61M | 10.78M | 10.68M |
| EPS | — | — | — | — |
| Profit Margin | -80,507.9% | 20.9% | 25.1% | 26.1% |
| Rev Growth | — | +20.4% | +3.7% | +1.7% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 1.04M | 212.35M | 210.18M | 232.91M |
| Total Equity | 280.24M | 340.13M | 367.41M | 326.92M |
| D/E Ratio | 0.00 | 0.62 | 0.57 | 0.71 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -547,638,914 | 17.18M | 13.92M | 13.69M |
| Free Cash Flow | — | 13.69M | 9.06M | 12.18M |